Is percutaneous nephrostomy for hydronephrosis appropriate in patients with advanced cancer?
Twenty patients with advanced pelvic malignancy and secondary hydronephrosis underwent percutaneous nephrostomy between July 1982 and October 1986. Improvement in renal function occurred in 17 patients (85 percent), and survival ranged from 4 days to 2 years. Median survival was 13 weeks, and 55 percent of the patients required multiple hospitalizations for urosepsis. In addition, 55 percent required multiple tube changes. Thirty-five percent of the patients never left the hospital and an additional 35 percent spent less than 6 weeks at home before they died. Median survival for eight patients with primary cancers most frequently associated with carcinomatosis was 7 weeks, and 63 percent of these patients died during hospitalization. The factors of limited survival, significant morbidity, in-hospital mortality, and poor quality of life should be considered before recommending percutaneous nephrostomy in patients with advanced cancer.
Keidan
R D
RD
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.
Greenberg
R E
RE
Hoffman
J P
JP
Weese
J L
JL
D006760:Hospitalization; D006801:Humans; D006869:Hydronephrosis / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D009403:Nephrostomy, Percutaneous / Q000401:mortality; D010386:Pelvic Neoplasms / Q000150:complications / Q000401:mortality / Q000601:surgery*; D011183:Postoperative Complications / Q000401:mortality; D011788:Quality of Life; D012189:Retrospective Studies